BioReperia gains international recognition!

BioReperia has recently joined an international consortium of 10 partners under the umbrella of the H2020-MSCA-RISE program.   We are delighted to announce that our portfolio company BioReperia has taken part in an international consortium of 10 partners under the umbrella of the H2020-MSCA-RISE program. RISE program connects organizations from the academic and non-academic sectors […]

Interview with Scailyte’s CEO Peter Nestorov

In an interview on the platform for high-tech startups Venturelab, Peter confirms something that we were already starting to presume in Hemex; Scailyte is developing rapidly. “However, the learning curve has been and still is extremely steep – as the start-up develops rapidly, so do I, and that is really exciting”. As a founder and […]

Scailyte is finalist for Nature Research Spinoff Prize!

nature research awards logo

Congratulations to our portfolio company Scailyte for being selected among the 12 finalists for the Nature Research Spinoff Prize. The Spinoff Prize is a new Nature Research Award for early-stage university spinoff companies from around the world. The Award has been established by Nature Research in partnership with Merck to showcase and celebrate global excellence in […]

Annaida Technologies In The Top 10 for the W.A. De Vigier Award!

After the Top 16 was announced by the W.A. De Vigier in March, now the Top 10 finalists for this year’s Award are published. The winners will be announced in early June! We are particularly proud to see our portfolio company Annaida Technologies in the Top 10 and wish them and all the Top 10 Startups […]

Scailyte announces its new advisory board composed of world leading clinicians and scientists

Scailyte™ is an ETH Zürich Spin-off and Top100 Swiss Startup applying artificial intelligence to discover novel and ultra-sensitive biomarkers from single-cell data.Over the past 3 years, we have established ScaiVision™, a proprietary data analytics platform for clinical research, which enables us to achieve groundbreaking discoveries in multiple disease areas. We have validated our approach by […]